Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4415-4417
10.1182/blood-2022-157547